RESEARCH TRIANGLE PARK, N.C., Jan. 8, 2014 /PRNewswire/ -- Pappas Ventures, a life science venture capital firm, announced today that Scott Weiner, who joined the firm in 2006, has been promoted to Partner.
"We are pleased to recognize Scott's many contributions to the development and success of our firm," said Art Pappas, Managing Partner at Pappas Ventures. "His knowledge of the life sciences industry and broad transaction experience is valued immensely both by my Pappas colleagues and by our many portfolio companies."
Among the many Pappas Ventures portfolio companies with which Mr. Weiner has been involved, he played a key role in the firm's successful investments in TESARO, Achillion Pharmaceuticals and Athersys. He currently serves as a director for Gentis and Milestone Pharmaceuticals, and as an observer for IlluminOss Medical, Liquidia Technologies and Thrasos Therapeutics.
Before joining Pappas Ventures as a Principal, he was with Silverback Asset Management's life science fund where he focused on healthcare securities investing. Prior to Silverback, he spent three years at Chicago Growth Partners (formerly William Blair Capital Partners) as a Vice President focusing on healthcare venture capital investments. Previously, he spent three and a half years in investment banking at Lehman Brothers, where he worked in the healthcare group in New York covering biotechnology, medical devices and drug delivery; the financial sponsors/leveraged finance group in London, and the media/telecom group in Hong Kong.
Mr. Weiner earned a Bachelor of Science in biological anthropology and anatomy from Duke University and a Master of Business Administration from Duke University's Fuqua School of Business.
About Pappas Ventures
Founded in 1994, Pappas Ventures invests exclusively in the life sciences sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures – across the United States and Canada. On January 6, 2014, Medtronic announced that it had acquired Pappas Ventures portfolio company TYRX for $160 million plus performance-based milestone payments. TYRX is the fourth Pappas Ventures portfolio company to either go public or be sold in the past 18 months.
Pappas Ventures has more than $350 million in capital under management, and has guided the launch and/or development of 56 companies, including Plexxikon Inc. (acquired by Daiichi Sankyo), Cerexa (acquired by Forest Laboratories), Peninsula Pharmaceuticals (acquired by Johnson & Johnson), Syntonix (acquired by Biogen IDEC), LEAD Therapeutics (acquired by BioMarin Pharmaceutical), Chimerix (IPO), TESARO (IPO), NuVasive (IPO) and Arena Pharmaceuticals (IPO). For more information about Pappas Ventures, please visit www.pappasventures.com.
Ford S. Worthy
|SOURCE Pappas Ventures|
Copyright©2012 PR Newswire.
All rights reserved